Best Life Sciences Companies in Western Australia, Australia
The 58 best Life Sciences companies in Western Australia, Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Cynata.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Western Australia
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Cynata Stem cell and regenerative medicine company developing a platform for off-the-shelf production of Mesenchymal… | $32M | 45 mo ago | Public | — | 1998 | — | — | — |
| 2 | PYC Therapeutics Developer of the drug for retinal, liver and neuro-degenerative diseases | $30M | 38 mo ago | Public | Rohan Hockings CEO | 2001 | WordPressMySQLPHP+20 | 48 patents Peptide-based delivery systems for renal and neurogenetic therapeutic applications | 1 award |
| 3 | Creso Pharma Developer of cannabinoid therapeutics for multiple health purposes | $28M | 69 mo ago | Acquired | Marc Lustig CEO | 2015 | — | — | — |
| 4 | SUDA Pharmaceuticals Developer of oro-mucosal drug delivery technology for treating multiple diseases | $24M | 60 mo ago | Public | Stephen Carter Chairman & CEO | 1999 | — | 7 patents Anti‑metastatic therapies targeting platelet‑mediated cancer progression | — |
| 5 | Arovella Therapeutics Developer of cell therapies to treat cancer and neurological diseases | $23M | 18 mo ago | Public | — | 1999 | — | 2 patents Repurposing anagrelide for cancer therapy, especially metastatic thrombocytotic cancers | — |
| 6 | Orchid Provider of a genetic test for determining the health risk of babies 16Funding top 41%Tech top 42%Global bottom 36%Growth bottom 35% All 5 signals ▾Fundingtop 41% Techtop 42% Globalbottom 36% Growthbottom 35% Marketbottom 21% Funding: Raised $16.5M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Tech: 25 technologies across 4/8 capability areas · Cloud: Cloudflare, Vercel rank vs industry peers · Fliar Intelligence Index 16/100 | $16M | 31 mo ago | Series A | — | 2019 | TurbopackEmotionNode.js+13 | — | — |
| 7 | Proteomics International Medical technology company at the forefront of predictive diagnostics and bio-analytical services | $16M | 29 mo ago | Public | Richard Lipscombe Co-Founder & Managing Director | 2001 | WordPressMySQLPHP+11 | — | — |
| 8 | OncoRes Medical Developer of intraoperative imaging technology for surgical procedures 45Patents top 29%Funding top 32%Moat top 32%Innovation top 34% All 8 signals ▾Patentstop 29% Fundingtop 32% Moattop 32% Innovationtop 34% Newstop 39% Techtop 45% Globalbottom 35% Marketbottom 34% Patents: 48 patents matched (strict assignee match) · 23 filings since 2022 vs 25 in 2017-21 Funding: Raised $13.9M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $14M | 5 mo ago | Series B | — | 2014 | WixSentryEnvoy+15 | 48 patents Medical elastography and optical palpation devices for assessing tissue mechanical properties | 1 job opening · 1 partnership |
| 9 | Orthocell Developer of regenerative medicine for orthopedic diseases | $11M | 20 mo ago | Public | Paul Anderson Founder & CEO | 2006 | WordPressApple iCloud MailMicrosoft 365+28 | 94 patents Collagen-based regenerative implants and devices for soft tissue and nerve repair | — |
| 10 | PharmAust Developer of medicines for the treatment of neurodegenerative diseases | $5M | 51 mo ago | Public | — | 2000 | — | — | — |
| 11 | Phoenix Biosystem Developer of biomarker panels and assays for disease assessment and detection | $4M | 74 mo ago | Funding Raised | Kumar Subramanian CEO and Co-Founder | 2001 | — | — | — |
| 12 | Neurotech International Developer of therapeutics for multiple paediatric neurological disorders | $3M | 104 mo ago | Public | — | 2016 | WordPress Block EditorWordPressMySQL+21 | — | — |
| 13 | Avicena Systems Developer of biosecurity platform and hardware for pathogen testing | $3M | 28 mo ago | Funding Raised | Tony Fitzgerald Co-Founder & CEO | 2020 | — | 22 patents High-throughput bioassay and pathogen/genetic screening instrumentation | 1 partnership |
| 14 | Imugene Developer of a therapeutic vaccine for the treatment of cancer | $2M | 18 mo ago | Public | Leslie Chong CEO & MD | 2012 | WordPressMySQLPHP+23 | 15 patents Therapeutic cancer vaccines and oncolytic virus platforms for immune activation | — |
| 15 | Oz Sonotek Ultrasound-based cataract surgery devices | $1M | 182 mo ago | Deadpooled | Nigel Morlet Founder | 2011 | — | — | — |
| 16 | Argenica Therapeutics Developer of neuroprotective therapeutics for stroke and neural injuries | $971K | 12 mo ago | Public | Liz Dallimore CEO & Managing Director | 2019 | WordPressMySQLPHP+13 | 3 patents Neuroprotective peptide therapeutics for brain injury and neurodegeneration | 2 launchs · 1 partnership |
| 17 | Nemgenix Developer of plant-resistant traits | $593K | 162 mo ago | Funding Raised | Sean Hird Co-Founder & CEO | 2007 | — | — | — |
| 18 | Marine Biomedical Developer of a marine-based medical device for orthopedic disorders | $278K | 180 mo ago | Funding Raised | Patrick Moase CEO | 2004 | — | 7 patents Manufacturing engineered calcified tissue/bone graft substitutes for biomedical implants | — |
| 19 | Cortical Dynamics Developing a brain function monitor which acquires EEG data of anesthetized patients | $250K | 76 mo ago | Seed | — | 2004 | — | 42 patents Non‑invasive brain activity monitoring devices and methods for medical diagnostics | 1 award |
Top 12 Life Sciences companies in Western Australia
#1
Series B · Perth, Western Australia · founded 2014 · 31 employees$13.9Mraised▾
Developer of intraoperative imaging technology for surgical procedures. The company utilizes a combination of optical coherence tomography imaging and elastography to provide a rapid evaluation of tissue microarchitecture at a scale and resolution comparable to histology. on the development of an imaging probe that will enable breast cancer surgeons to identify residual cancer following the excision of a tumor, providing a solution to address the high re-excision rates for breast cancer patients.
- Feb 2026Series B$19.2M
- Oct 2022Grant (prize money)$942.2K
- May 2022Grant (prize money)$3M
- May 2022Series A$9.5M
#2
Public · Perth, Western Australia · founded 1999 · 44 employees$23Mraised▾
Developer of cell therapies to treat cancer and neurological diseases. The company is focusing on the development of a natural killer T (iNKT) cell therapy platform for the treatment of human diseases. ZolpiMist is a first-in-class oral spray of zolpidem tartrate to treat short-term insomnia. The company is developing other products to treat migraine, headaches, motion sickness, blood cancers, malignant tumors, and drug-resistant epilepsy.
- Jan 2025Post IPO$20M
- Jan 2022Post IPO$3M
#3
Public · Perth, Western Australia · founded 2006$11.2Mraised▾
Developer of regenerative medicine for orthopedic diseases. It offers Striate+ a resorbable collagen membrane for dental applications, Remplir a collagen scaffold for peripheral nerve repair, and OrthoACI autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle.
- Oct 2024Post IPO$11.2M
#4
Public · Armadale, Western Australia · founded 2012 · 5 employees$2.4Mraised▾
Developer of a therapeutic vaccine for the treatment of cancer. The company uses oncolytic virus and B-cell immunotherapy technology to treat a variety of cancers. Its lead product includes HER-Vaxx (HER-2 + B-cell peptide) and a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.
- Dec 2024Post IPO$28.7M
- Sep 2022Post IPO$53.9M
- Nov 2019Post IPO$16.6M
- Jul 2018Post IPO$8.9M
#5
Public · Nedlands, Western Australia · founded 2019$970.9Kraised▾
Developer of neuroprotective therapeutics for stroke and neural injuries. The company's product line include ARG-007 is a cationic and arginine-rich peptide drug administered intravenously. It has the ability to slow the progression of brain injury and preserve brain cells.
- Jun 2025Grant (prize money)$970.9K
#6
Public · Perth, Western Australia · founded 2001$15.5Mraised▾
Medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company develop and commercializes diagnostic tests known as PromarkerD, for the detection of diabetic kidney disease. Company specialises in the area of proteomics, the industrial scale study of the structure and function of proteins. It also, offers analytical services for research purposes. The technology can be used to identify fingerprints from any biological source, from wheat seeds to human serum.
- Jan 2024Post IPO$4.3M
- Aug 2022Post IPO$5.7M
- May 2022Grant (prize money)$413.5K
- Nov 2021Grant (prize money)$74.6K
#7
Series A · Armadale, Western Australia · founded 2019 · 10 employees$16.5Mraised▾
Provider of a genetic test for determining the health risk of babies. The platform collects the saliva sample from both the parents and provides the genetic influence on the child's health. The results are provided for brain health, heart health, cancer, and overall health. A personalized consultation is provided from fertility experts and genetic counselors on diet, fitness, and health.
- Dec 2023Series A$12M
- Apr 2021Seed$4.5M
#8
Public · Armadale, Western Australia · founded 1998 · 2 employees$32.2Mraised▾
Cynata Therapeutics is an Australian stem cell and regenerative medicine company that is developing a therapeutic stem cell platform technology, Cymerus™, originating from the University of Wisconsin-Madison, a world leader in stem cell research. The proprietary Cymerus™ technology seeks to address a critical shortcoming in existing methods of production of mesenchymal stem cells (MSCs) for therapeutic use, which is the ability to achieve economic manufacture at commercial scale. Cymerus™ does so through the production of a particular type of MSC precursor, called a mesenchymoangioblast (MCA). The Cymerus™ MCA platform provides a source of MSCs that is independent of donor limitations and provides a potential “off-the-shelf” stem cell platform for therapeutic product use, with a pharmaceutical business model and economies of scale.
- Sep 2022Grant (prize money)$1M
- Dec 2020Post IPO$11.2M
- Oct 2019Grant (prize money)$34.1K
- Dec 2018Grant (prize money)—
#9
Public · Nedlands, Western Australia · founded 2001 · 25 employees$30Mraised▾
Developer of the drug for retinal, liver, and neuro-degenerative diseases. The company offers proprietary CPP (Cell-Penetrating Peptides) technology and RNA-based therapeutics for treating retinal diseases, like Retinitis Pigmentosa responsible for childhood blindness. The company also has a pipeline for neurodegenerative disorders and liver disorders.
- May 2023PE$30M
#10
Public · Perth, Western Australia · founded 1999$23.9Mraised▾
Developer of oro-mucosal drug delivery technology for treating multiple diseases. The company utilizes its proprietary OroMist, an oro-mucosal drug delivery technology to develop drugs that improve the health and lifestyle of patients. It offers ZolpiMist, an oral spray of zolpidem for insomnia; ArTiMist, a sub-lingual spray in the development stage for the treatment of malaria in children. The product pipeline also includes oral sprays of sumatriptan for migraine (SUD-001), ondansetron for chemotherapy-induced nausea and vomiting (SUD-002), sildenafil for erectile dysfunction (SUD-003) and PAH (SUD-004), and midazolam for pre-procedural anxiety (SUD-005).
- Jun 2021Post IPO$3.6M
- Dec 2020Post IPO$2.7M
- Aug 2020Post IPO$4.1M
- Nov 2013Post IPO$5.6M
#11
Acquired · Perth, Western Australia · founded 2015 · 23 employees$27.5Mraised▾
Developer of cannabinoid therapeutics for multiple health purposes. The company has developed therapeutics for human and veterinary applications using nanotechnology. The company's lead products are cannabidiol hemp oil-based complementary feed for companion animals and a nutraceutical for human health.
- Oct 2020Post IPO—
- Jun 2020Post IPO$1.4M
- Jan 2019Post IPO$3M
- Nov 2017Post IPO$17.5M
#12
Funding Raised · Perth, Western Australia · founded 2020 · 20 employees$3Mraised▾
Developer of biosecurity platform and hardware for pathogen testing. The company has developed a technology for testing pathogens. They created the Avicena Sentinel, a molecular diagnostics platform with an hourly screening capacity of thousands of samples. Additionally, they are engaged in the development of microLED-based ultra-low energy optical links.
- Feb 2024Grant (prize money)$3M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Australia
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 861 Australia-affiliated papers.
- University College London67
- The University of Queensland63
- The University of Melbourne59
- Agriculture and Food54
- La Trobe University35
- Mutant2→11
- Genome1→7
- Immune system1→5
- Antibody1→4
- Mitochondrion2→4
- Gene5→17
- Immune system2→13
- Antibody1→10
- Messenger RNA1→10
- Mutant1→9
- Agriculture5→19
- Sustainability3→8
- Emerging technologies1→4
- Resistance (ecology)3→6
- Bacteria2→5
Where biotechnology is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.